Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
Sarah Bencardino, Ferdinando D’Amico, Ilaria Faggiani, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 5014-5014
Open Access | Times Cited: 25

Showing 25 citing articles:

Overcoming the challenges of overtreating and undertreating inflammatory bowel disease
María José Temido, Sailish Honap, Vipul Jairath, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 2
Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023
Saghir Ali, Andrew A. Bolinger, Jia Zhou
Current Topics in Medicinal Chemistry (2024) Vol. 24, Iss. 10, pp. 843-849
Open Access | Times Cited: 9
Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials
Sara Massironi, Federica Furfaro, Sarah Bencardino, et al.
Journal of Gastroenterology (2024) Vol. 59, Iss. 9, pp. 761-787
Open Access | Times Cited: 7
Safety and Effectiveness of Thiopurines and Small Molecules in Elderly Patients with Inflammatory Bowel Diseases
Aleksandra Strigáč, M Caban, Ewa Małecka‐Panas, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4678-4678
Open Access | Times Cited: 4
Positionspapier der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung (GPGE) zum zulassungsüberschreitenden Gebrauch von für Erwachsene mit CED zugelassenen Biologika und Signalinhibitoren bei Kindern und Jugendlichen
Jan Däbritz, Martin Claßen, K. Krohn, et al.
Zeitschrift für Gastroenterologie (2025)
Open Access
A practical approach to positioning therapies in ulcerative colitis
Russell Yanofsky, David T. Rubin
Journal of the Canadian Association of Gastroenterology (2025) Vol. 8, Iss. Supplement_2, pp. S6-S14
Open Access
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis
Vipul Jairath, Tim Raine, Thomas P. Leahy, et al.
Journal of Comparative Effectiveness Research (2025)
Closed Access
Contribution of S1pr1-featured astrocyte subpopulation to cisplatin-induced neuropathic pain
Ying Li, Silvia Squillace, Rachel Schafer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Etrasimod: Review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis
Javier P. Gisbert, María Chaparro
Gastroenterología y Hepatología (English Edition) (2025), pp. 502363-502363
Closed Access
The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis
Xin Yi Choon, Jie Han Yeo, Christopher J. White, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 10, pp. 3475-3475
Open Access
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn’s Disease
S. Harris, Brian G. Feagan, Stephen B. Hanauer, et al.
Digestive Diseases and Sciences (2024) Vol. 69, Iss. 6, pp. 2044-2054
Open Access | Times Cited: 3
Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand
Antonietta Gerarda Gravina, Raffaele Pellegrino, Giovanna Palladino, et al.
Biomolecules (2024) Vol. 14, Iss. 9, pp. 1164-1164
Open Access | Times Cited: 3
Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases
Irene Mignini, Giulia Piccirilli, Fabrizio Termite, et al.
Cells (2023) Vol. 13, Iss. 1, pp. 90-90
Open Access | Times Cited: 8
Discovery of Potent, Orally Bioavailable Sphingosine-1-Phosphate Transporter (Spns2) Inhibitors
Daniel J. Foster, Kyle Dunnavant, Christopher W. Shrader, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11273-11295
Open Access | Times Cited: 2
Development and validation of stability-indicating method of etrasimod by HPLC/DAD/MS/MS technique with greenness profiling
Jelena Kovačić, Daniela Amidžić Klarić, Nikša Turk, et al.
Heliyon (2024) Vol. 10, Iss. 13, pp. e34066-e34066
Open Access | Times Cited: 2
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis
Sophie Vieujean, Laurent Peyrin-Biroulet
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 9, pp. 881-892
Closed Access | Times Cited: 2
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management
Konstantina Kitsou, Georgios Kokkotis, Jesús Rivera–Nieves, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Targeting mucosal healing in Crohn’s disease: efficacy of novel pathways and therapeutic targets
Lucia Centanni, Sarah Bencardino, Ferdinando D’Amico, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 11, pp. 963-978
Closed Access | Times Cited: 2
Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine
Mariam S Mukhtar, Mahmoud Mosli
Saudi Journal of Gastroenterology (2024) Vol. 30, Iss. 3, pp. 126-137
Open Access | Times Cited: 1
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons
Walter Reinisch, Gil Y. Melmed, Hiroshi Nakase, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3832-3849
Open Access | Times Cited: 1
Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials
Jingyue Qiu, Jiakuo Liu, Kexin Cai, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Raising the bar in ulcerative colitis management
Fabrizio Fanizzi, Mariangela Allocca, Gionata Fiorino, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
TO MARKET, TO MARKET—2023: SMALL MOLECULES
Erika Araujo, Björn Bartels, Ian M. Bell, et al.
Medicinal chemistry reviews (2024), pp. 417-551
Closed Access
Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program
Marla C. Dubinsky, Joseph Wu, Aoibhinn McDonnell, et al.
Journal of Crohn s and Colitis (2024)
Open Access
IgG4 in the gut: Gastrointestinal IgG4-related disease or a new subtype of inflammatory bowel disease
Sarah Bencardino, Cosimo Simone Matichecchia, Jacopo Fanizza, et al.
Autoimmunity Reviews (2024) Vol. 24, Iss. 2, pp. 103720-103720
Closed Access
Page 1

Scroll to top